Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer

NCT ID: NCT03801876Sponsor: NRG OncologyLast updated: 2026-05-07

Summary

This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.

Detailed description

PRIMARY OBJECTIVES: I. To determine if overall survival (OS) is improved with proton beam radiation therapy (PBT) treatment as compared to intensity modulated photon radiation therapy (IMRT) as part of planned protocol treatment for patients with esophageal cancer. II. To determine if OS with PBT is non-inferior to IMRT as part of planned protocol treatment and that there will be less grade 3+ cardiopulmonary toxicity with PBT than with IMRT. SECONDARY OBJECTIVES: I. To compare the symptom burden and impact on functioning of patients between treatment modalities based on Patient Reported Outcome (PRO) measures of symptoms using MD Anderson Symptom Inventory (MDASI) and Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue. II. To compare the Quality-Adjusted Life Years (QALY) using EuroQol five-dimensional questionnaire (EQ5D) as a health outcome between PBT and IMRT, if the protocol primary endpoint is met. III. To assess the pathologic response rate between PBT and IMRT. IV. To assess the cost-benefit economic analysis of treatment between radiation modalities. V. To compare the length of hospitalization after protocol surgery between PBT and IMRT. VI. To compare the incidence of grade 4 lymphopenia during chemoradiation between PBT and IMRT. VII. To compare lymphocyte nadir at first follow-up visit after completion of chemoradiation between PBT \& IMRT. VIII. To estimate the locoregional failure, distant metastatic free survival, and progression-free survival of patients treated with PBT versus IMRT. IX. To compare incidence of both early (\< 90 days from treatment start) and late (≥ 90 days from treatment start) cardiovascular and pulmonary events between PBT versus IMRT. X. To compare the total toxicity burden (TTB) of IMRT versus PBT based on a composite index of 9 individual cardiopulmonary toxicities. EXPLORATORY OBJECTIVES: I. To collect biospecimens for future analyses, for example to assess cardiac and inflammatory biomarkers in association with treatment complications. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients undergo PBT over 28 fractions 5 days a week for 5.5 weeks. Patients also receive chemotherapy consisting of carboplatin/paclitaxel, or fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX)/capecitabine-oxaliplatin (CAPOX), or docetaxel/fluorouracil (5-FU, with capecitabine an acceptable substitute for 5-FU), as determined by the patient and their treating physician while undergoing PBT. GROUP II: Patients undergo IMRT over 28 fractions 5 days a week for 5.5 weeks. Patients also receive chemotherapy consisting of carboplatin/paclitaxel, or FOLFOX/CAPOX, or docetaxel/5-FU (with capecitabine an acceptable substitute for 5-FU) as determined by the patient and their treating physician while undergoing IMRT. In both groups, within 4-8 weeks after completion of chemotherapy and radiation therapy, patients should undergo an esophagectomy if it's determined that the patient can tolerate an esophagectomy and whether the tumor is surgically resectable. Additionally, patients undergo blood sample collection, and positron emission tomography (PET)/computed tomography (CT) or CT throughout the study. After completion of study treatment, patients are followed up every 3-6 months for 3 years and then annually thereafter.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • DrugCapecitabine

    Oral

  • DrugCarboplatin

    Given IV

  • ProcedureComputed Tomography

    Undergo CT or PET/CT

  • DrugDocetaxel

    IV

  • ProcedureEsophagectomy

    Undergo esophagectomy

  • DrugFluorouracil

    IV

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT

  • DrugLeucovorin Calcium

    Oral

  • DrugOxaliplatin

    IV

  • DrugPaclitaxel

    Given IV

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

  • RadiationProton Beam Radiation Therapy

    Undergo PBT

  • OtherQuality-of-Life Assessment

    Ancillary studies

  • OtherQuestionnaire Administration

    Ancillary studies

Outcome measures

Primary

  • Overall survival (OS)

    Will be estimated by the Kaplan-Meier method. The distributions of OS between treatment arms will be compared using the log rank test.

    Time frame: From the date of randomization to the date of death due to any cause or date of last follow-up for patients without an OS event reported. This analysis occurs after 173 deaths; estimated to occur 4 years after accrual completion

  • Incidence of specific grade 3+ cardiopulmonary adverse events (AEs) that are definitely, probably, or possibly related to protocol treatment

    Will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Difference in proportion of defined cardiopulmonary AEs will be analyzed with a chi-squared test.

    Time frame: From baseline up to 8 years

Secondary

  • Change in patient reported outcomes (PROs) of symptom and function

    Time frame: Baseline up to 12 months after end of chemoradiation

  • Pathologic response rate

    Time frame: At time of surgery

  • Length of hospitalization

    Time frame: From baseline up to 8 years

  • Grade 4 lymphopenia during chemoradiation

    Time frame: From baseline up to 8 years

  • Lymphocyte counts

    Time frame: From baseline up to 8 years

  • Locoregional failure (LRF)

    Time frame: From the date of randomization to the date of first LRF or date of last follow-up for patients without an LRF event reported, assessed up to 8 years

  • Distant metastatic-free survival (DMFS)

    Time frame: From the date of randomization to the date of first DMFS failure or last follow-up for patients without a reported DMFS event, assessed up to 8 years

  • Progression-free survival

    Time frame: From the date of randomization to the date of first PFS failure or last follow-up for patients without a reported PFS event, assessed up to 8 years

  • Quality-adjusted life years (QALY)

    Time frame: Assessed up to 8 years

  • Cost-benefit economic analysis of treatment

    Time frame: Assessed up to 8 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * PRIOR TO STEP 1 REGISTRATION: * Histologically proven diagnosis of adenocarcinoma or squamous cell carcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II) * Stage I-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition based on the following diagnostic workup: * History/physical examination * Whole-body fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) with or without contrast (preferred) or chest/abdominal (include pelvic if clinically indicated) CT with contrast * For patients who DID NOT receive induction chemotherapy, scan must occur within 30 days prior to Step 1 registration * For patients who DID receive induction chemotherapy, scan must occur: * Within 30 days after final induction chemotherapy dose; OR * Within 30 days prior to Step 1 registration * Note: Patients who had prior endoscopic mucosal resection (EMR) with a diagnosis of AJCC stage I-IVA, excluding T4b, esophageal cancer are eligible * Surgical consultation to determine whether or not the patient is a candidate for resection after completion of chemoradiation * Induction chemotherapy for the current malignancy prior to concurrent chemoradiation allowed if last dose is no more than 90 days and no less than 10 days prior to Step 1 registration; only FOLFOX, CAPOX, durvalumab-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) (D-FLOT) and FLOT will be allowed as the induction chemotherapy regimen * Age ≥ 18 * Zubrod performance status 0, 1, or 2 * Absolute neutrophil count (ANC) (within 30 days prior to Step 1 registration) * For patients who DID NOT receive induction chemotherapy: ANC ≥ 1,500 cells/mm\^3 * For patients who DID receive induction chemotherapy: ANC ≥ 1,000 cells/mm\^3 * Platelets (within 30 days prior to Step 1 registration) * For patients who DID NOT receive induction chemotherapy: Platelets ≥ 100,000/uL * For patients who DID receive induction chemotherapy: Platelets ≥ 75,000/uL * Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable) (within 30 days prior to Step 1 registration) * Serum creatinine ≤ 1.5 X upper limit of normal (ULN) or creatinine clearance \> 40 mL/min estimated by Cockcroft-Gault formula (within 30 days prior to Step 1 registration) * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 30 days prior to Step 1 registration) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN (within 30 days prior to Step 1 registration) * Negative pregnancy test (serum or urine) within 14 days prior to Step 1 registration for women of child bearing potential * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry Exclusion Criteria: * Cervical esophageal cancers arisen from 15-18 cm from the incisors * Patients with T4b disease according to the AJCC 8th edition * Definitive clinical or radiologic evidence of metastatic disease * Any active malignancy within 2 years of study registration that may alter the course of esophageal cancer treatment * Prior thoracic radiotherapy that would result in overlap of radiation therapy fields * Severe, active co-morbidity defined as follows: * Active uncontrolled infection requiring IV antibiotics at the time of Step 1 registration * Uncontrolled symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia not controlled by any device or medication at the time of Step 1 registration * Myocardial infarction within 3 months prior to Step 1 registration * Pregnant and/or nursing females * Human immunodeficiency virus (HIV) positive with CD4 count \< 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive * PRIOR TO STEP 2 REGISTRATION: * Unable to obtain confirmation of payment coverage (insurance or other) for either possible radiation treatment

Study locations (95)

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054

Active Not Recruiting

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259

Active Not Recruiting

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205

Recruiting
Site Public Contact · Contact
501-686-8274
Fen Xia · Principal Investigator

UM Sylvester Comprehensive Cancer Center at Coral Gables

Coral Gables, Florida, 33146

Recruiting
Site Public Contact · Contact
305-243-2647
William Jin · Principal Investigator

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442

Recruiting
Site Public Contact · Contact
305-243-2647
William Jin · Principal Investigator

UM Sylvester Comprehensive Cancer Center at Doral

Doral, Florida, 33166

Recruiting
Site Public Contact · Contact
kginnity@med.miami.edu
William Jin · Principal Investigator

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136

Recruiting
Site Public Contact · Contact
305-243-2647
William Jin · Principal Investigator

Miami Cancer Institute

Miami, Florida, 33176

Recruiting
Site Public Contact · Contact
786-596-2000
Michael D. Chuong · Principal Investigator

UM Sylvester Comprehensive Cancer Center at Kendall

Miami, Florida, 33176

Recruiting
Site Public Contact · Contact
305-243-2647
William Jin · Principal Investigator

Orlando Health Cancer Institute

Orlando, Florida, 32806

Active Not Recruiting

UM Sylvester Comprehensive Cancer Center at Plantation

Plantation, Florida, 33324

Recruiting
Site Public Contact · Contact
305-243-2647
William Jin · Principal Investigator

Emory Proton Therapy Center

Atlanta, Georgia, 30308

Active Not Recruiting

Emory University Hospital Midtown

Atlanta, Georgia, 30308

Active Not Recruiting

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Active Not Recruiting

Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342

Active Not Recruiting

Alton Memorial Hospital

Alton, Illinois, 62002

Recruiting
Site Public Contact · Contact
618-463-7323
Gregory R. Vlacich · Principal Investigator

Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, 60115

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Neal D. Andruska · Principal Investigator

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Neal D. Andruska · Principal Investigator

Memorial Hospital East

Shiloh, Illinois, 62269

Recruiting
Site Public Contact · Contact
314-747-9912dschwab@wustl.edu
Gregory R. Vlacich · Principal Investigator

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Neal D. Andruska · Principal Investigator

Maryland Proton Treatment Center

Baltimore, Maryland, 21201

Recruiting
Site Public Contact · Contact
410-369-5226info@mdproton.com
Jason K. Molitoris · Principal Investigator

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201

Recruiting
Site Public Contact · Contact
800-888-8823
Jason K. Molitoris · Principal Investigator

UM Upper Chesapeake Medical Center

Bel Air, Maryland, 21014

Active Not Recruiting

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114

Recruiting
Site Public Contact · Contact
877-726-5130
Florence K. Keane · Principal Investigator

McLaren Cancer Institute-Bay City

Bay City, Michigan, 48706

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Brian K. Yeh · Principal Investigator

Corewell Health Dearborn Hospital

Dearborn, Michigan, 48124

Recruiting
Site Public Contact · Contact
248-551-7695
John M. Robertson · Principal Investigator

Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Brian K. Yeh · Principal Investigator

Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Brian K. Yeh · Principal Investigator

McLaren Cancer Institute-Flint

Flint, Michigan, 48532

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Brian K. Yeh · Principal Investigator

Karmanos Cancer Institute at McLaren Greater Lansing

Lansing, Michigan, 48910

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Brian K. Yeh · Principal Investigator

McLaren Cancer Institute-Lapeer Region

Lapeer, Michigan, 48446

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Brian K. Yeh · Principal Investigator

McLaren Cancer Institute-Owosso

Owosso, Michigan, 48867

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Brian K. Yeh · Principal Investigator

Corewell Health William Beaumont University Hospital

Royal Oak, Michigan, 48073

Recruiting
Site Public Contact · Contact
248-551-7695
John M. Robertson · Principal Investigator

Corewell Health Beaumont Troy Hospital

Troy, Michigan, 48085

Recruiting
Site Public Contact · Contact
248-551-7695
John M. Robertson · Principal Investigator

Mayo Clinic Health System in Albert Lea

Albert Lea, Minnesota, 56007

Completed

Mercy Hospital

Coon Rapids, Minnesota, 55433

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Charles Shideman · Principal Investigator

Unity Hospital

Fridley, Minnesota, 55432

Active Not Recruiting

Mayo Clinic Health Systems-Mankato

Mankato, Minnesota, 56001

Completed

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Charles Shideman · Principal Investigator

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Charles Shideman · Principal Investigator

Mayo Clinic Radiation Therapy-Northfield

Northfield, Minnesota, 55057

Active Not Recruiting

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Active Not Recruiting

Ridgeview Medical Center

Waconia, Minnesota, 55387

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Charles Shideman · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Gregory R. Vlacich · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Gregory R. Vlacich · Principal Investigator

Mercy Hospital Springfield

Springfield, Missouri, 65804

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Gregory R. Vlacich · Principal Investigator

Mercy Hospital South

St Louis, Missouri, 63128

Recruiting
Site Public Contact · Contact
314-525-6042Danielle.Werle@mercy.net
Jay W. Carlson · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Gregory R. Vlacich · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Gregory R. Vlacich · Principal Investigator

Mercy Hospital Saint Louis

St Louis, Missouri, 63141

Recruiting
Site Public Contact · Contact
314-251-7066
Jay W. Carlson · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Abraham J. Wu · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Abraham J. Wu · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Abraham J. Wu · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Abraham J. Wu · Principal Investigator

Memorial Sloan Kettering Westchester

East White Plains, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
Abraham J. Wu · Principal Investigator

New York Proton Center

New York, New York, 10035

Recruiting
Site Public Contact · Contact
646-968-9031ichoi@nyproton.com
Jehee I. Choi · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Abraham J. Wu · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Abraham J. Wu · Principal Investigator

UH Seidman Cancer Center at UH Avon Health Center

Avon, Ohio, 44011

Recruiting
Site Public Contact · Contact
800-641-2422
Lauren E. Henke · Principal Investigator

UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, 44122

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

Geauga Hospital

Chardon, Ohio, 44024

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Recruiting
Site Public Contact · Contact
513-584-7698cancer@uchealth.com
Jordan Kharofa · Principal Investigator

Case Western Reserve University

Cleveland, Ohio, 44106

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting
Site Public Contact · Contact
800-293-5066Jamesline@osumc.edu
Russell F. Palm · Principal Investigator

Mercy Cancer Center-Elyria

Elyria, Ohio, 44035

Suspended

UH Seidman Cancer Center at Landerbrook Health Center

Mayfield Heights, Ohio, 44124

Suspended

UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor, Ohio, 44060

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

UH Seidman Cancer Center at Southwest General Hospital

Middleburg Heights, Ohio, 44130

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

University Hospitals Parma Medical Center

Parma, Ohio, 44129

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

University Hospitals Portage Medical Center

Ravenna, Ohio, 44266

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

UH Seidman Cancer Center at Firelands Regional Medical Center

Sandusky, Ohio, 44870

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

University Hospitals Sharon Health Center

Wadsworth, Ohio, 44281

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Recruiting
Site Public Contact · Contact
513-584-7698cancer@uchealth.com
Jordan Kharofa · Principal Investigator

UH Seidman Cancer Center at Saint John Medical Center

Westlake, Ohio, 44145

Suspended

UHHS-Westlake Medical Center

Westlake, Ohio, 44145

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Lauren E. Henke · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Andrea Johnston · Principal Investigator

University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104

Recruiting
Site Public Contact · Contact
215-349-8245PMCancerResearch@pennmedicine.upenn.edu
John P. Plastaras · Principal Investigator

Covenant Health Proton Center

Knoxville, Tennessee, 37909

Recruiting
Site Public Contact · Contact
865-531-5118jwilso31@covhlth.com
Grant M. Clark · Principal Investigator

Covenant Health Cancer Centers

Knoxville, Tennessee, 37916

Recruiting
Site Public Contact · Contact
865-331-1812
Grant M. Clark · Principal Investigator

Covenant Health Cancer Centers - West

Knoxville, Tennessee, 37932

Recruiting
Site Public Contact · Contact
865-331-1812
Grant M. Clark · Principal Investigator

Covenant Health Oncology Group - Maryville

Maryville, Tennessee, 37804

Suspended

Covenant Health Oncology Group - Oak Ridge

Oak Ridge, Tennessee, 37830

Recruiting
Site Public Contact · Contact
865-331-1812
Grant M. Clark · Principal Investigator

MD Anderson in The Woodlands

Conroe, Texas, 77384

Recruiting
Site Public Contact · Contact
866-632-6789askmdanderson@mdanderson.org
Saumil Gandhi · Principal Investigator

M D Anderson Cancer Center

Houston, Texas, 77030

Recruiting
Site Public Contact · Contact
877-632-6789askmdanderson@mdanderson.org
Saumil Gandhi · Principal Investigator

MD Anderson West Houston

Houston, Texas, 77079

Recruiting
Site Public Contact · Contact
877-632-6789askmdanderson@mdanderson.org
Saumil Gandhi · Principal Investigator

MD Anderson League City

League City, Texas, 77573

Recruiting
Site Public Contact · Contact
877-632-6789askmdanderson@mdanderson.org
Saumil Gandhi · Principal Investigator

MD Anderson in Sugar Land

Sugar Land, Texas, 77478

Recruiting
Site Public Contact · Contact
877-632-6789askmdanderson@mdanderson.org
Saumil Gandhi · Principal Investigator

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Shane Lloyd · Principal Investigator

Inova Alexandria Hospital

Alexandria, Virginia, 22304

Active Not Recruiting

Inova Schar Cancer Institute

Fairfax, Virginia, 22031

Active Not Recruiting

Inova Fair Oaks Hospital

Fairfax, Virginia, 22033

Active Not Recruiting

Inova Loudoun Hospital

Leesburg, Virginia, 20176

Active Not Recruiting

University of Washington Medical Center - Montlake

Seattle, Washington, 98195

Active Not Recruiting

Mayo Clinic Health System-Eau Claire Clinic

Eau Claire, Wisconsin, 54701

Completed

References

  • Muijs CT, Klaver YLB, Nuyttens J, Lips IM, Muller K, Ebrahimi GM, Dankers FJWM, Verhoeven R, Schuit E, Berbee M. National indication protocol for proton radiotherapy in esophageal cancer patients in the Netherlands. Radiother Oncol. 2025 Dec;213:111164. doi: 10.1016/j.radonc.2025.111164. Epub 2025 Sep 24.(PubMed)